Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Summary

Participation Requirements

Description

Brain tumors are the first cause of cancer mortality in children and the 3rd cause in young adults. The most frequent brain tumors are gliomas and among them the most common type is astrocytoma. The most malignant astrocytoma is Glioblastoma (GBM). Standard therapy of newly diagnosed GBM patients in...

Brain tumors are the first cause of cancer mortality in children and the 3rd cause in young adults. The most frequent brain tumors are gliomas and among them the most common type is astrocytoma. The most malignant astrocytoma is Glioblastoma (GBM). Standard therapy of newly diagnosed GBM patients includes surgery, irradiation and temozolomide (TMZ) chemotherapy with 1-year and 5-year survival rates at 30% and 3%, respectively. For the treatment of recurrent GBM, TMZ is widely used even if the optimal dosing schedule and the minimal time interval from first line are unknown. Other appropriate therapeutic options include Lomustine, an alkylating drug, and Bevacizumab, an anti-angiogenic agent targeting VEGF-A, approved only in selected countries (i.e. North America, Switzerland). Controlled trials are rare for recurrent glioblastoma, consequently therapeutic decisions are mostly based on low-level evidence. Amongst innovative strategies, immunotherapy is considered as one of the most promising. Immunotherapy stimulates the natural properties of the immune system to protect against cancer growth. Therapeutic vaccines (active immunotherapy) are expected to elicit a cytotoxic immune response to tumor-associated antigens, destroying malignant cells without harming normal cells. The cells involved in this response are T lymphocytes, which can sense abnormal peptides at the tumor cells surface. One critical step towards the development of therapeutic vaccines was the identification and validation of glioma antigens. This is an obstacle the investigators have circumvented with the characterization of several immunogenic glioma peptides by screening the peptidome of ex vivo human glioma samples. This led to the development of a multipeptide vaccine called IMA950. IMA950 is composed of 9 synthetic tumor-associated HLA-A2-restricted peptides (TUMAPs), two MHC class II-binding peptides and one HLA-A2-restricted HBV-derived peptide, the latter used as marker of vaccine immunogenicity. The HLA-A2 allele is expressed by approximately 45% of the Swiss population. As the interactions between peptides and their corresponding HLA molecule are highly specific, only HLA-A*02 positive patients will be included in this trial. The reasons why this set of peptides is very promising for vaccination are as follows: Tumor peptides have been isolated from ex vivo samples: They are over-expressed in glioma (compared to normal tissues) They are derived from proteins involved in the malignant process They are immunogenic in vitro in healthy donors and in glioma patients This is a MULTI-peptide vaccine IMA950 was investigated in a monocentric phase I/II trial for newly diagnosed glioblastoma and WHO grade III gliomas using poly-ICLC as adjuvant (PI: P-Y. Dietrich, NCT01920191, study completed, final results in preparation for publication). A total of 19 patients (16 with GBM and 3 with anaplastic astrocytoma) were included, with a median number of 9 injections received per patient (range: 4-11). The multipeptide vaccine did not show any serious safety issues, apart from some mild inflammatory reactions at the injection site, peritumoral or resection cavity edema/tumor flare manageable with steroids, as well as peri-vaccinational transient mild headache, fatigue and flu-like syndrome (grade 3 events: 42.1%, grade 4 events: 21%, no grade 5 events). Regarding vaccine immunogenicity, CD4 T-cell responses were detected in the majority of patients (58%) and were usually sustained. The CD8 T-cell responses were detected in 63% of patients, with 37% of them being multi-TUMAP responders. Median overall survival from date of surgery was 21 months (range: 10 - 41 months) for the overall cohort, with a 19 months survival for the GBM-only cohort (range: 10-41 months), which compares favorably with the reported median survival of 15 months with the reference treatment of temozolomide-based chemoradiation. PFS was 93% and 56% at 6 and 9 months respectively. Despite the T cell ability to detect tumor peptides that are naturally presented by tumor cells, these T cells do not normally become activated and do not protect the body against the cancer, as tumor cells on their own are only poorly immunogenic. For effective T cell activation, the help of co-stimulatory molecules, which are expressed on activated professional APCs, e.g. dendritic cells, is required. During infections, the activation of APCs is triggered by molecular patterns common to all pathogens of a class (e.g. RNA viruses). These patterns, also referred to as "danger signals", are not provided by peptides themselves. Consequently, artificial danger signals have to be provided with a tumor vaccine to induce the required co-stimulation on APCs. In combination with a vaccine, such substances with a non-specific immunostimulatory effect are called adjuvants. Poly-ICLC, (Hiltonol®, Oncovir) is a synthetic double-stranded ribo-nucleic acid (dsRNA) mimicking viral pathogen associated molecular patterns (PAMP) that activates multiple elements of innate and adaptive immunity. The importance of intact immune surveillance in controlling outgrowth of neoplastic cells has been known for decades. The PD-1 receptor-ligand interaction is a major pathway hijacked by tumors to suppress immune control. The normal function of PD-1, expressed on the cell surface of activated T-cells under healthy conditions, is to down-regulate unwanted or excessive immune responses, including autoimmune reactions. Binding of PD-1 ligands (PD-L1 and PD-L2) to the PD-1 receptor inhibits T-cell activation triggered through the T-cell receptor. Pembrolizumab (Keytruda™) is a potent and highly selective humanized monoclonal antibody (mAb) designed to directly block the interaction between PD-1 and its ligands. Impressive response rate and prolonged survival were first observed for metastatic melanoma, but the clinical benefit of this mAb was recently shown to extend to several other cancer types. There is a strong rationale to investigate the role of PD-1/PD-L1 blockade in malignant glioma, since (i) we and others have previously reported that PD-L1 expression by glioma cells may contribute to tumor-related immunoresistance; (ii) PD-L1 is also expressed by tumor-infiltrating macrophages and circulating monocytes; (iii) expression of PD-L1 on circulating monocytes was shown to correlate with worsened survival in patients who received the HSPPC-96 vaccine for newly diagnosed and recurrent GBM. The 200 mg Q3W dose will maintain individual patient exposures within the exposure range demonstrated to be well tolerated, safe and established in melanoma as associated with maximal efficacy response. A fixed dose regimen simplifies the dosing regimen so as to be more convenient for physicians and to reduce the potential for dosing errors. The combination of pembrolizumab with a vaccine therapy is currently being tested in several trials for different tumors, such as melanoma, bladder, colorectal and prostate cancer (NCT02574533, NCT02054520, NCT02432963, NCT02499835, NCT02515227). Here the investigators postulate that Pembrolizumab may improve the immunogenicity of the IMA950 vaccine and the function of vaccine-induced glioma-specific T cells, and that the multipeptide vaccine may help to focus the immune response against antigens overexpressed by glioma, leading together to an optimization of the antitumor immune effect whilst reducing the risk of collateral damage to the brain. The study aims to answer questions regarding safety (for the future clinical development of this strategy), immunogenicity (synergy between multipeptide vaccine and pembrolizumab) and clinical outcome. Ancillary translational research should help to identify possible correlation between neo-epitopes, methylation status, immune response and clinical outcome.

Tracking Information